Andrew Joseph from STAT News, Slashdot - Journalist Profile

	Profile	Recent Articles on Subject
1	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Galapagos to split itself into two companies as part of turnaround plan - 14 days ago Surgeon general calls for labels warning of cancer risk on alcohol - 19 days ago STAT+: Novartis to pay $1 billion upfront to license Huntington’s drug from PTC - about 2 months ago STAT+: New report urges guidelines — and some restrictions — on stem cell-based embryo models - about 2 months ago STAT+: Amgen drug leads to substantial weight loss in study, but questions remain about competitiveness - about 2 months ago Top FDA official says Trump and RFK Jr. will mean ‘vigorous dialogue’ on vaccines - 2 months ago STAT+: With RFK Jr. looming as health secretary, pharma execs try to project stability - 2 months ago STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 3 months ago STAT+: Novo Nordisk reports continued growth in obesity drug sales - 3 months ago STAT+: Novartis, Seagen veteran David Epstein is back, leading a new cancer startup - 3 months ago STAT+: CVS Health replaces CEO as it faces a range of challenges - 3 months ago News from ESMO: An AstraZeneca win in bladder cancer, and more - 4 months ago STAT+: AstraZeneca’s Imfinzi increases survival rates in bladder cancer in pivotal study - 4 months ago STAT+: Incyte’s checkpoint inhibitor staves off disease progression in anal cancer trial - 4 months ago STAT+: Pfizer drug shows promise in cancer-related condition that causes weight loss and weakness - 4 months ago STAT+: Bristol immunotherapy improves responses in lung cancer, setting up Phase 3 study - 4 months ago STAT+: Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target - 4 months ago The news from ESMO: The latest on anti-TIGIT data, a PD-(L)1 injection, and more - 4 months ago STAT+: A new drug offers a rare option for brain cancer treatment — and inspires hopes for more - 4 months ago STAT+: U.K.’s cost-effectiveness agency gives negative review of Alzheimer’s drug Leqembi - 5 months ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 5 months ago STAT+: FDA approves innovative T cell immunotherapy for rare soft-tissue cancer - 6 months ago STAT+: Jim Wilson, gene therapy pioneer, departs Penn to set up new companies - 6 months ago STAT+: Pharmalittle: We’re watching positive Zepbound cardiovascular data, a move to take 23andMe private, and more - 6 months ago STAT+: A second Roche obesity drug shows promise in early studies - 6 months ago USDA maintains bird flu can be eliminated from dairy cows, even as doubts mount among experts - 6 months ago STAT+: Europe is set to shake up the way it assesses new medicines. Gene therapy makers are worried - 7 months ago European regulators find no evidence of link between new obesity medicines and suicidal thoughts - 9 months ago STAT+: Big biotech names roll out Seaport Therapeutics, as interest in neuropsychiatric drugs swells - 10 months ago STAT+: Early data from rare-disease trial put spotlight on Moderna’s efforts to turn mRNA into medicines - 10 months ago STAT+: Genmab to buy ProfoundBio for $1.8 billion, the latest deal focused on targeted chemotherapies - 10 months ago STAT+: Viking Therapeutics to move its oral obesity drug into Phase 2 study after early success - 10 months ago STAT+: Novo Nordisk to acquire heart disease-focused Cardior Pharmaceuticals in deal worth $1.1 billion - 10 months ago STAT+: Feng Zhang suggests Editas didn’t move quickly enough to find product targets - 10 months ago STAT+: A scientific mystery highlights the blind spots in genomics databases - 10 months ago STAT+: As targeted radiation field heats up, AstraZeneca to acquire Fusion Pharmaceuticals in $2 billion deal - 10 months ago STAT+: Vertex hits speed bump in getting CRISPR sickle cell therapy covered in U.K. - 10 months ago STAT+: AstraZeneca picks up rare disease-focused Amolyt Pharma in $1 billion deal - 10 months ago STAT+: In surprise move, FDA calls for advisory committee on Lilly’s Alzheimer’s drug - 11 months ago STAT+: Novo Nordisk’s diabetes drug Ozempic cuts risk of kidney disease progression, trial shows - 11 months ago Amid measles outbreaks, U.K. launches vaccination ad campaign to boost childhood immunizations - 11 months ago STAT+: Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH - 11 months ago STAT+: As Medicare drug pricing negotiations begin, AstraZeneca stays mum on government’s offer - 12 months ago STAT+: A gene therapy designed to heal skin wounds helped preserve a boy’s vision - 12 months ago Scientists Document First-Ever Transmitted Alzheimer's Cases, Tied To No-Longer-Used Medical Procedure - 12 months ago Scientists document first-ever transmitted Alzheimer’s cases, tied to no-longer-used medical procedure - 12 months ago STAT+: From a small town in Wales, a scientific sleuth has shaken Dana-Farber — and elevated the issue of research integrity - 12 months ago Two genomics powerhouses team up to expand infectious disease surveillance - 12 months ago STAT+: U.K. sequencing study surfaces new findings about tumor DNA - about 1 year ago STAT+: GSK to acquire Aiolos Bio in $1.4 billion deal, picking up an experimental asthma drug - about 1 year ago
2	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 3 months ago
3	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 3 months ago
4	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 3 months ago
5	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 3 months ago
6	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Novo Nordisk reports continued growth in obesity drug sales - 3 months ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 5 months ago
7	Tara Bannow STAT News Reporter @statnews. healthcarejournalism	STAT+: CVS Health replaces CEO as it faces a range of challenges - 3 months ago
8	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 5 months ago